StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX - Free Report) in a research note released on Thursday. The brokerage issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Trading Down 0.6 %
BTX traded down $0.04 during midday trading on Thursday, reaching $6.40. The company's stock had a trading volume of 358,564 shares, compared to its average volume of 788,400. Brooklyn ImmunoTherapeutics has a 1 year low of $5.10 and a 1 year high of $8.31. The stock's 50-day moving average is $6.30 and its 200-day moving average is $2.82. The firm has a market capitalization of $376.49 million, a price-to-earnings ratio of -2.82 and a beta of 4.61.
Brooklyn ImmunoTherapeutics Announces Dividend
The business also recently disclosed a monthly dividend, which was paid on Monday, March 31st. Shareholders of record on Friday, March 14th were paid a dividend of $0.0862 per share. This represents a $1.03 dividend on an annualized basis and a yield of 16.15%. The ex-dividend date was Friday, March 14th. Brooklyn ImmunoTherapeutics's payout ratio is -44.05%.
About Brooklyn ImmunoTherapeutics
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Recommended Stories
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
